<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92526">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02054754</url>
  </required_header>
  <id_info>
    <org_study_id>ETS2101-101</org_study_id>
    <nct_id>NCT02054754</nct_id>
  </id_info>
  <brief_title>Assessment of Single Doses of Oral Dexanabinol in Healthy Subjects</brief_title>
  <official_title>Assessment of Safety, Tolerability and Pharmacokinetics of Single Doses of Oral Dexanabinol in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>e-Therapeutics PLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>e-Therapeutics PLC</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety and observe the pharmacokinetics
      (distribution and elimination of the drug) of the compound dexanabinol (ETS2101) in healthy
      male subjects following a single oral dose.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Safety and tolerability based on the number of participants with adverse events and comparison of baseline and post dose parameters</measure>
    <time_frame>Participants will be followed until follow up visit, 6-11 days after dosing</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety and tolerability based on the number of participants with adverse events. Assessment and comparison to baseline of the following:
Physical exam
Safety bloods and urinalysis
12-lead ECG
Vital signs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under curve (AUC)</measure>
    <time_frame>Pre-dose, 0.5,1,1.5,2,3,4,5,6,8,10,12,16,24,36,48 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacokinetic parameters will be assessed in a blinded fashion at the end of each cohort, prior to dose escalation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacodynamic biomarker assessment</measure>
    <time_frame>Pre-dose, 1, 6 and 24 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood samples taken and analysed for the purposes of the identification and quantification of pharmacodynamic biomarkers pre-dose and at several points after dosing.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Safety</condition>
  <condition>Tolerability</condition>
  <condition>Pharmacokinetics</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Dexanabinol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of dexanabinol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single oral dose of matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexanabinol</intervention_name>
    <description>Oral formulation of dexanabinol</description>
    <arm_group_label>Dexanabinol</arm_group_label>
    <other_name>ETS2101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males aged 18 to 45 years

          -  Body mass index 18.0 to 32.0 kg/m2, or if outside the range, considered not
             clinically significant by the investigator

        Exclusion Criteria:

          -  Participation in a clinical research study within the previous 3 months

          -  Current smokers and those who have smoked within the last 12 months

          -  History of any drug or alcohol abuse in the past 2 years
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Evans, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Clinical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philip Evans, MD</last_name>
    <phone>+44 115 974 9000</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Quotient Clinical</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philip Evans, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 3, 2014</lastchanged_date>
  <firstreceived_date>November 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dexanabinol</keyword>
  <keyword>Oral</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>HU 211</mesh_term>
    <mesh_term>Tetrahydrocannabinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
